Objective: to identify potential predisposing and modifying factors of MG in order to improve understanding of the mechanisms of disease, diagnostics and treatment.
ID
Source
Brief title
Condition
- Neuromuscular disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Main study parameters/endpoints:
Primary endpoint: Comparison of potential predisposing and modifying factors
between Dutch and Norwegian MG patients.
.
Secondary outcome
Secondary endpoint: Comparison of demography, quality of life and differences
in medical treatment between Dutch MG patients and Norwegian MG patients
Background summary
Myasthenia Gravis or the Lambert-Eaton myasthenic syndrome are an acquired
chronical autoimmune neuromuscular disorders. The pathogenesis of Myasthenia
Gravis is unclear and deserves further investigation. Prevailing theories are
involving complex immunogenetic, environmental and hormonal agents.
Epidemiological studies of Myasthenia gravis patients across Europe involving a
large number of patients will improve the knowledge of clinical, psycho-social
and environmental factors affecting the course of MG.
Study objective
Objective: to identify potential predisposing and modifying factors of MG in
order to improve understanding of the mechanisms of disease, diagnostics and
treatment.
Study design
Study design: cross sectional cohort study
Methods: By means of a self- administered questionnaire (E-MG questionnaire)
and SF-36.
Study burden and risks
Nature and extent of the burden and risks associated with participation is
considered minimal (one questionnaire has to be filled in). There are no direct
benefits for the participant, but with this information we hope to optimize the
diagnostics and treatment in the future.
Postbus 9600
2300 RC leiden
NL
Postbus 9600
2300 RC leiden
NL
Listed location countries
Age
Inclusion criteria
criteria 1 and 2 or 1 and 3 have to be fulfilled
1. Clinical weakness compatible with a from of myasthenia
2. Electromyographic evicence consistent with a neuromuscular transmission defect
3. Elevated serum antibody levels against ACHR, MuSK or VGCC
Exclusion criteria
Age of < 18 years
Lack of both criteria 2 and 3
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL36673.058.11 |